HSV 863
Alternative Names: Human anti-HSV antibodyLatest Information Update: 13 Nov 2002
Price :
$50 *
At a glance
- Originator Novartis
- Developer Nonindustrial source; PDL BioPharma
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Herpes simplex virus infections
Most Recent Events
- 21 May 2001 Profile reviewed but no significant changes made